Avid Bioservices Inc (CDMO)

[investingdog]

Here is the whole article:

http://ir.peregrineinc.com/releasedetail.cfm?releaseid=655805

and more

http://www.biotechnologyevents.com/node/4122

This part isn't very encouraging, essentially same as control:

" patients treated with bavituximab plus carboplatin and paclitaxel demonstrated an ORR of 25%, versus 23% in patients treated with carboplatin and paclitaxel alone. Investigator-determined response rates were 32% for bavituximab plus carboplatin and paclitaxel versus 31% for carboplatin and paclitaxel alone."

and this

" The trial completed enrollment in September of 2011 and median OS from this trial is event-driven and anticipated in the fourth quarter of 2012."

Announcement of Median OS is now more than six months late. If the response is so weak how can the trial take so long to reach the trigger point. Doesn't make sense. Sandbagging?